Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pelthos Therapeutics (PTHS) Long-Term Investments (2022 - 2023)

Pelthos Therapeutics has reported Long-Term Investments over the past 1 years, most recently at $181576.0 for Q4 2023.

For Q4 2023, Long-Term Investments changed N/A year-over-year to $181576.0; the TTM value through Dec 2023 reached $181576.0, changed N/A, while the annual FY2023 figure was $181576.0, N/A changed from the prior year.
Long-Term Investments for Q4 2023 was $181576.0 at Pelthos Therapeutics.
Over five years, Long-Term Investments peaked at $181576.0 in Q4 2023 and troughed at $181576.0 in Q4 2023.